Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

被引：0
|
作者：
Geetha, Duvuru [1 ]
Cortazar, Frank [2 ]
Bruchfeld, Annette [3 ]
Karras, Alexandre [4 ]
Merkel, Peter [5 ]
Jayne, David [6 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] New York Nephrol, Watervliet, NY USA
[3] Karolinska Inst, Stockholm, Sweden
[4] HEGP APHP, Paris, France
[5] Univ Penn, Philadelphia, PA USA
[6] Univ Cambridge, Cambridge, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0683
引用
收藏
页码：1363 / 1364
页数：2
相关论文
共 50 条
  • [1] Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with ANCA-Associated Vasculitis with Renal Involvement Treated with Avacopan
    Rauen, Thomas
    Geetha, Duvuru
    Cortazar, Frank B.
    Bruchfeld, Annette
    Karras, Alexandre
    Merkel, Peter A.
    Jayne, David R.
    INNERE MEDIZIN, 2024, 65 : S155 - S155
  • [2] Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
    Geetha, Duvuru
    Dua, Anisha
    Yue, Huibin
    Salvarani, Carlo
    Jayne, David
    Merkel, Peter
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1366 - 1367
  • [3] Glucocorticoid Use and Related Adverse Events in ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis
    De Gomma, Emil
    Merkel, Peter
    George, Michael
    Rhee, Rennie
    Kronbichler, Andreas
    Jayne, David
    Yue, Huibin
    Bekker, Pirow
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2144 - 2146
  • [4] The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
    Strand, Vibeke
    Bekker, Pirow
    Yue, Huibin
    Jayne, David R. W.
    Merkel, Peter
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1990 - 1992
  • [5] The Effect on Health-Related Quality of Life of Treatment for Remission Maintenance in ANCA-Associated Vasculitis Beyond 18 Months
    Tomasson, Gunnar
    Sreih, Antoine G.
    Cuthbertson, David
    Carette, Simon
    Khalidi, Nader A.
    Koening, Curry L.
    Langford, Carol A.
    McAlear, Carol A.
    Monach, Paul A.
    Moreland, Larry W.
    Seo, Philip
    Specks, Ulrich
    Ytterberg, Steven R.
    Merkel, Peter A.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [6] General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
    Hajj-Ali, Rula A.
    Geetha, Duvuru
    Luqmani, Raashid
    Pagnoux, Christian
    Trimpe, Darcy
    Jayne, David
    Merkel, Peter
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5046 - 5047
  • [7] Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
    Pagnoux, Christian
    Neel, Antoine
    Bray, Sarah
    Gurlin, Rachel E.
    Trimpe, Darcy
    Jayne, David
    Merkel, Peter
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5038 - 5040
  • [8] DIFFERENCES BETWEEN AVACOPAN AND PREDNISONE FOR THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS AT DIFFERENT THRESHOLDS OF GLUCOCORTICOID TOXICITY
    Patel, N.
    Zhang, Y.
    Jayne, D.
    Merkel, P. A.
    Yue, H.
    Bekker, P.
    Stone, J. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 707 - 708
  • [9] A RANDOMIZED PHASE 3 TRIAL EVALUATING THE SAFETY AND EFFICACY OF AVACOPAN IN PATIENTS WITH NEW OR RELAPSING ANCA-ASSOCIATED VASCULITIS
    Merkel, Peter
    Jayne, David
    Harigai, Masayoshi
    Schall, Thomas
    Bekker, Pirow
    Potarca, Antonia
    Hillson, Jan
    RHEUMATOLOGY, 2019, 58
  • [10] Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
    Spiera, Robert
    Lebovics, Robert
    Bray, Sarah
    Gurlin, Rachel E.
    Jayne, David
    Merkel, Peter
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5043 - 5045
12345